CN Patent

CN111479560A — 用于治疗非转移性去势难治性前列腺癌的抗雄激素

Assigned to Aragon Pharmaceuticals Inc · Expires 2020-07-31 · 6y expired

What this patent protects

本文描述了使用经批准的含有阿帕鲁胺、恩杂鲁胺或达罗鲁胺的药物产品治疗非转移性去势难治性前列腺癌的方法。本文还描述了含有阿帕鲁胺、恩杂鲁胺或达罗鲁胺的药物产品，以及销售或许诺销售抗雄激素药物产品的方法。

USPTO Abstract

本文描述了使用经批准的含有阿帕鲁胺、恩杂鲁胺或达罗鲁胺的药物产品治疗非转移性去势难治性前列腺癌的方法。本文还描述了含有阿帕鲁胺、恩杂鲁胺或达罗鲁胺的药物产品，以及销售或许诺销售抗雄激素药物产品的方法。

Drugs covered by this patent

Patent Metadata

Patent number
CN111479560A
Jurisdiction
CN
Classification
—
Expires
2020-07-31
Drug substance claim
No
Drug product claim
No
Assignee
Aragon Pharmaceuticals Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.